H
Henk M. Lokhorst
Researcher at VU University Medical Center
Publications - 71
Citations - 7485
Henk M. Lokhorst is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Multiple myeloma & Daratumumab. The author has an hindex of 31, co-authored 71 publications receiving 6001 citations. Previous affiliations of Henk M. Lokhorst include University of Amsterdam & Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more
TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Journal ArticleDOI
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
Meletios A. Dimopoulos,Evangelos Terpos,Raymond L. Comenzo,Patrizia Tosi,Meral Beksac,Orhan Sezer,David S. Siegel,Henk M. Lokhorst,Shaji Kumar,S V Rajkumar,Ruben Niesvizky,Lia A. Moulopoulos,Brian G.M. Durie +12 more
TL;DR: Bone scintigraphy has no place in the routine staging of myeloma, whereas sequential dual-energy X-ray absorptiometry scans are not recommended, and Positron emission tomography/CT or MIBI imaging are also not recommended for routine use in the management of Myeloma patients.